Related Experiment Video

Updated: May 20, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?

Liam M McCormick1, Anna C Kydd, David P Dutka

  • 1Department of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, UK.

Cardiovascular & Hematological Agents in Medicinal Chemistry
|July 26, 2012
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) pathway drugs show promise for improving heart health in type 2 diabetes patients. Research explores their cardiovascular benefits beyond glucose control.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death in type 2 diabetes mellitus (T2DM).
  • Improved glycemic control reduces microvascular complications but has less defined effects on cardiovascular events.
  • The incretin axis, particularly glucagon-like peptide-1 (GLP-1) pathways, offers novel therapeutic targets.

Purpose of the Study:

  • To review myocardial energy metabolism in T2DM.
  • To present evidence on incretin effects on the heart.
  • To discuss the potential benefits of GLP-1 modulating drugs for cardiovascular outcomes in T2DM patients with coronary artery disease.

Main Methods:

  • Review of pre-clinical and clinical studies on incretin effects.
  • Analysis of myocardial energy metabolism, focusing on glucose utilization.
  • Discussion of potential mechanisms of action for GLP-1 pathway drugs.

Main Results:

  • GLP-1 pathways have established effects on glucose homeostasis.
  • Emerging evidence suggests pleiotropic cardiovascular effects of incretins.
  • Potential benefits include improved myocardial energy metabolism and glucose utilization.

Conclusions:

  • GLP-1 modulating drugs may offer cardiovascular benefits in T2DM patients.
  • Further research is warranted to elucidate mechanisms and clinical efficacy.
  • These agents represent a promising therapeutic strategy for managing CVD risk in T2DM.

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...